((Chloroquine OR Hydroxychloroquine) AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
3,969 results
- Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar. [Journal Article]Qatar Med J. 2022; 2022(3):37.QM
- CONCLUSIONS: In Qatar, patients with ARDs had an overall higher prevalence of COVID-19 than global estimates. Being male and having close contact with a COVID-19 case were strongly associated with COVID-19 as reported globally. The presence of comorbid conditions, disease-specific factors, and rheumatic medications had no significant effect on the risk of COVID-19 in our study suggesting alternative mechanisms to the increased prevalence.
- PMC Free PDF
- Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties. [Journal Article]
- A series of 1″-(alkylsulfonyl)-dispiro[indoline-3,2'-pyrrolidine-3',3″-piperidine]-2,4″-diones 6a‒o has been synthesized through regioselective multi-component azomethine dipolar cycloaddition reaction of 1-(alkylsulfonyl)-3,5-bis(ylidene)-piperidin-4-ones 3a‒h. X-ray diffraction studies (6b‒d,h) confirmed the structures. The majority of the synthesized analogs reveal promising antiproliferation …
- Publisher Full Text (DOI)
- Slight High-Frequency Hearing Loss, Effect of COVID-19 or Hydroxychloroquine Usage? [Journal Article]Otol Neurotol. 2022 Aug 17 [Online ahead of print]ON
- CONCLUSIONS: Slight hearing loss was seen in patients with COVID-19 with or without HCQ. Also, hearing thresholds in the HCQ+ group did not show a significant difference compared with the HCQ- group. Nevertheless, it seems that more damage is done to the hair cells of patients with HCQ intake than in other patients. Hence, the ototoxicity effect of high doses of HCQ use in the COVID-19 patients should be considered. A relative improvement in the hearing was seen over time in both patient groups.
- Publisher Full Text
- Lived experiences of recovered COVID-19 persons in Nigeria: A phenomenological study. [Journal Article]PLoS One. 2022; 17(8):e0268109.Plos
- CONCLUSIONS: We conclude that persons who recovered from COVID-19 in Nigeria had varied experiences relating to the mode of infection, the clinical features, methods of treatment, and psychosocial effects of the virus. These experiences would be useful for designing and implementing appropriate interventions, policies, and programs for managing the pandemic in the country.
- FREE Publisher Full Text
- How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. [Review]Intern Med J. 2022 Aug 15 [Online ahead of print]IM
- Hydroxychloroquine (HCQ) and its close relative chloroquine (CQ) were initially used as antimalarial agents but are now widely prescribed in rheumatology, dermatology and immunology for the management of autoimmune diseases. HCQ is considered to have a better long-term safety profile than CQ and is therefore more commonly used. HCQ has a key role in the treatment of connective tissue diseases inc…
- Publisher Full Text (DOI)
- Cuttlefish bone powder as an efficient solid-phase extraction sorbent of anti-SARS-CoV-2 drugs in environmental water. [Journal Article]
- Many antiviral drugs were developed to counteract coronavirus disease, 2019 (COVID-19) with severe acute respiratory syndrome. Therefore, the scientific community's efforts have focused on the detection and quantification of antiviral compounds currently being tested for COVID-19 treatment. Cuttlefish bone powder (CFBP) has been used for the first time as solid-phase extraction (SPE) sorbent for …
- PMC Free Full TextPMC Free PDF
- Obesity and clinical outcomes in COVID-19 patients without comorbidities, a post-hoc analysis from ORCHID trial. [Journal Article]
- CONCLUSIONS: Obesity was independently linked to prolonged hospital length of stay in COVID-19 without any comorbidity. Larger prospective trials are required to assess the role of obesity in COVID-19 related deaths.
- PMC Free PDF
- In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. [Journal Article]Chem Biol Interact. 2022 Aug 11 [Online ahead of print]CB
- Remdesivir (RDV, Veklury®) is an FDA-approved prodrug for the treatment of hospitalized patients with COVID-19. Recent in vitro studies have indicated that human carboxylesterase 1 (CES1) is the major metabolic enzyme catalyzing RDV activation. COVID-19 treatment for hospitalized patients typically also involves a number of antibiotics and anti-inflammatory drugs. Further, individuals who are car…
- Publisher Full Text
- Authors' reply to: "Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine". [Letter]J Eur Acad Dermatol Venereol. 2022 Aug 14 [Online ahead of print]JE
- Publisher Full Text
- Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City. [Journal Article]Br J Clin Pharmacol. 2022 Aug 12 [Online ahead of print]BJ
- CONCLUSIONS: This study in severely ill patients was not able to find any relationship between systemic exposure to HCQ and DHCQ and clinical outcome at a routine dose regimen and adds to the growing body of evidence that oral HCQ does not alter the course of disease in COVID-19 patients.
- Publisher Full Text
- Neutrophil autophagy and NETosis in COVID-19: perspectives. [Review]Autophagy. 2022 Aug 11 [Online ahead of print]A
- The COVID-19 pandemic has caused substantial losses worldwide in people's lives, health, and property. Currently, COVID-19 is still prominent worldwide without any specific drug treatment. The SARS-CoV-2 pathogen is the cause of various systemic diseases, mainly acute pneumonia. Within the pathological process, neutrophils are recruited to infected sites, especially in the lungs, for the first st…
- Publisher Full Text
- Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review. [Review]
- CONCLUSIONS: This rapid scoping review characterised a growing body of comparative-effectiveness primary studies and evidence syntheses. The results suggest future studies should focus on children, elderly ≥65 years of age, patients with mild symptoms, outpatient treatment, multimechanism therapies, harms and active comparators. The results also suggest that future living evidence synthesis and network meta-analysis would provide additional information for decision-makers on managing COVID-19.
- FREE Publisher Full TextPMC Free Full TextPMC Free PDF
- Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. [Review]
- CONCLUSIONS: A benefit of HCQ as prophylaxis for COVID-19 cannot be ruled out based on the available evidence from randomized trials. However, the "not statistically significant" findings from early prophylaxis trials were widely interpreted as definite evidence of lack of effectiveness of HCQ. This interpretation disrupted the timely completion of the remaining trials and thus the generation of precise estimates for pandemic management before the development of vaccines.
- Publisher Full TextPMC Free Full TextPMC Free PDF
- Bis(thio)carbohydrazone Luminogens with AIEE and ACQ Features and Their In Silico Investigations with SARS-CoV-2. [Journal Article]
- Herein, we report two novel multidentate luminogen proligands bis(3,5-diiodosalicylidene) carbohydrazone (H4L1) and bis(3,5-diiodosalicylidene) thiocarbohydrazone (H4L2), which are suitable candidates for biomedical applications. Though the thiocarbohydrazone H4L2 shows aggregation caused quenching (ACQ), the carbohydrazone H4L1 exhibits stronger fluorescence due to aggregation induced emission e…
- PMC Free PDF
- Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [Review]
- The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the ongoing pandemic named COVID-19 which causes a serious emergency on public health hazards of international concern. In the face of a critical medical emergency, repositioning of drugs is one of the most authentic options to design an adequate treatment for infected patients immediately. In this strategy, Remdesivir …
- Publisher Full TextPMC Free Full TextPMC Free PDF
- Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Impact of Hydroxychloroquine (HCQ) as Post-exposure Prophylaxis and Early Treatment for COVID-19. [Journal Article]J Med Virol. 2022 Aug 08 [Online ahead of print]JM
- Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either post-exposure prophylaxis (PEP) or early treatment of SARS-CoV-2 infection. Using data from these studies, we calculated time-weighted average change from baseline SARS-CoV-2 viral load and demonstrated that HCQ did not affect viral clearance. This article is protected by copyright. All rights…
- Publisher Full Text
- Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. [Journal Article]
- CONCLUSIONS: The target sample size was not met. Our findings are compatible with both benefit and harm of pre-exposure prophylaxis with TDF/FTC and HCQ, alone or in combination, compared with placebo.
- Publisher Full TextPMC Free Full TextPMC Free PDF
- Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. [Journal Article]
- Background: COVID-19 patients with underlying medical conditions are vulnerable to drug-drug interactions (DDI) due to the use of multiple medications. We conducted a discovery-driven data analysis to identify potential DDIs and associated adverse events (AEs) in COVID-19 patients from the FDA Adverse Event Reporting System (FAERS), a source of post-market drug safety. Materials and Methods: We i…
- FREE Publisher Full TextPMC Free Full TextPMC Free PDF
- Management of neonatal sepsis with COVID-19 infection in a premature newborn - A case report. [Case Reports]
- CONCLUSIONS: The basics of treatment for neonatal COVID-19 is supportive care. Some studies have treated infants with various drugs such as Hydroxychloroquine, Favipiravir, and Remedsivir; however, in our case, a 5-day-old baby boy was treated with corticosteroids and IVIg. We achieved good outcomes after 2 weeks of treatment with dexamethasone 0.3 mg/kg per day and IVIg 2 g/kg/day (for 3 days). It appears that these treatments, along with adjuvant ventilation and the administration of endotracheal surfactant, can improve a patient's general condition.
- PMC Free Full TextPMC Free PDF
- Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. [Randomized Controlled Trial]
- CONCLUSIONS: Using response-adaptive randomisation within RECOVERY could have increased the number of patients receiving the optimal COVID-19 treatment during the trial, while reducing the number of patients needed to attain the same study power as the original study. This would likely have reduced patient deaths during the trial and lead to dexamethasone being declared effective sooner. Deciding how to balance the needs of patients within a trial and future patients who have yet to fall ill is an important ethical question for the trials community to address. Response-adaptive randomisation deserves to be considered as a design feature in future trials of COVID-19 and other diseases.
- FREE Publisher Full TextPMC Free Full TextPMC Free PDF
- Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. [Journal Article]
- CONCLUSIONS: Dry powder HCQ inhalations were well tolerated by the participants, except for transient bitter taste in all participants and minor coughing irritation. There was no significant change in QTc-interval or drop in FEV1 post inhalation. The serum HCQ concentration remained below 10 μg/L in all samples.Single doses of inhaled dry powder HCQ up to 20 mg are safe and well tolerated. Our data support that further studies with inhaled HCQ dry powder to evaluate pulmonary pharmacokinetics and efficacy are warranted.
- PMC Free PDF
- A Review of Clinical Efficacy Data Supporting Emergency Use Authorization for COVID-19 Therapeutics and Lessons for Future Pandemics. [Review]Clin Transl Sci. 2022 Aug 04 [Online ahead of print]CT
- Emergency Use Authorization (EUA) allows the U.S. Food and Drug Administration (FDA) to expedite the availability of therapeutics in the context of a public health emergency. To date, an evidentiary standard for clinical efficacy to support an EUA has not yet been established. This review examines the clinical data submitted in support of EUA for anti-viral and anti-inflammatory therapeutics for …
- Publisher Full Text
- Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. [Journal Article]
- CONCLUSIONS: During the COVID-19 pandemic, medication treatment patterns evolved reliably in response to emerging evidence and changes in policy. These findings may inform efforts to promote optimal adoption and deadoption of treatments for acute care conditions.
- PMC Free PDF
- Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania. [Journal Article]J Environ Qual. 2022 Aug 02 [Online ahead of print]JE
- During the COVID-19 pandemic, wastewater surveillance was leveraged as a powerful tool for monitoring community-scale health. Further, the well-known persistence of some pharmaceuticals through wastewater treatment plants spurred concerns that increased usage of pharmaceuticals during the pandemic would increase the concentrations in wastewater treatment plant effluent. We collected weekly influe…
- Publisher Full Text
- Synthesis of pyrazolo[5',1':2,3]imidazo[1,5-c]quinazolin-6(5H)-ones and molecular docking study of their affinity against the COVID-19 main protease. [Journal Article]
- A novel series of fused pyrazolo[5',1':2,3]imidazo[1,5-c]quinazolin-6(5H)-ones were synthesized and their affinity against the COVID-19 main protease was investigated using molecular docking study and compared to that of some used standard clinical drugs. These compounds were obtained in good to excellent yields from 63 to 91% in the presence of 30 mol% catalyst in ethanol at reflux for 2 h throu…
- PMC Free PDF
- Study on Hydroxychloroquinine Sulfate Being Given to the Admitted COVID -19 Positive Patients at Institute of JLNMCH, Bhagalpur, Bihar, India. [Journal Article]
- Background As the global death toll from new coronavirus illness (COVID-19) rises, the scientific community and healthcare systems are under massive pressure to manage the outbreak and develop effective medical remedies. Meanwhile, desperation has pushed practitioners, scientists, and authorities to recommend and attempt medicines with little or no proof. Despite the lack of clear and unequivocal…
- PMC Free PDF
- A Randomized Controlled Trial of Combined Ivermectin and Zinc Sulfate versus Combined Hydroxychloroquine, Darunavir/Ritonavir, and Zinc Sulfate among Adult Patients with Asymptomatic or Mild Coronavirus-19 Infection. [Journal Article]
- CONCLUSIONS: We demonstrated that both treatment regimens were safe, but both treatment regimens had no virological or clinical benefit. Based on this result and current data, there is no supporting evidence for the clinical benefit of ivermectin for coronavirus-19.
- PMC Free PDF
- COVID-19: Pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies. [Journal Article]Curr Pharm Des. 2022 Jul 29 [Online ahead of print]CP
- COVID-19, a dreaded and highly contagious pandemic, is flagrantly known for its rapid prevalence across the world. Till date, none of the treatments are distinctly accessible for this life-threatening disease. Under the prevailing conditions of medical emergency, one creative strategy for the identification of novel and potential antiviral agents gaining momentum in research institutions and prog…
- Publisher Full Text
- Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab. [Journal Article]
- This study evaluates the use of the Global Pharma Health Fund (GPHF) Minilab for medicine quality screening by 16 faith-based drug supply organizations located in 13 low- and middle-income countries. The study period included the year before the COVID-19 pandemic (2019) and the first year of the pandemic (2020). In total 1,919 medicine samples were screened using the GPHF Minilab, and samples sho…
- PMC Free PDF
- Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York City. [Journal Article]J Clin Rheumatol. 2022 Jul 29 [Online ahead of print]JC
- CONCLUSIONS: During the initial peak of the pandemic in New York City, patients with versus without SRD hospitalized with COVID-19 had a 24% increased likelihood of having severe COVID-19 after multivariable adjustment.
- Publisher Full Text